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Abstract
Background: Affecting both livestock and humans, Rift Valley Fever is considered as one of the
most important viral zoonoses in Africa. However, no licensed vaccines or effective treatments are
yet available for human use. Naked DNA vaccines are an interesting approach since the virus is
highly infectious and existing attenuated Rift Valley Fever virus vaccine strains display adverse
effects in animal trials. In this study, gene-gun immunisations with cDNA encoding structural
proteins of the Rift Valley Fever virus were evaluated in mice. The induced immune responses were
analysed for the ability to protect mice against virus challenge.
Results: Immunisation with cDNA encoding the nucleocapsid protein induced strong humoral and
lymphocyte proliferative immune responses, and virus neutralising antibodies were acquired after
vaccination with cDNA encoding the glycoproteins. Even though complete protection was not
achieved by genetic immunisation, four out of eight, and five out of eight mice vaccinated with
cDNA encoding the nucleocapsid protein or the glycoproteins, respectively, displayed no clinical
signs of infection after challenge. In contrast, all fourteen control animals displayed clinical
manifestations of Rift Valley Fever after challenge.
Conclusion:  The appearance of Rift Valley Fever associated clinical signs were significantly
decreased among the DNA vaccinated mice and further adjustment of this strategy may result in
full protection against Rift Valley Fever.
Background
Rift Valley Fever virus (RVFV) is a mosquito-borne Phlebo-
virus in the Bunyaviridae family. RVFV infects domesticated
ruminants and humans and regularly induces epizootics
with concomitant epidemics throughout the African con-
tinent and on the Arabian Peninsula [1,2]. Outbreaks
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among domesticated ruminants are characterised by a
large increase of spontaneous abortions and the case fatal-
ity rate may reach 100% in young animals [3]. While Rift
Valley Fever (RVF) is generally benign in man, more
severe clinical manifestations such as hemorrhagic fever,
encephalitis and retinitis are regulary observed [4].
Despite the fact that RVF is an important viral zoonosis,
and the risk for emergence in new susceptible areas has
been emphasized [1], effective and safe vaccines are not
commercially available. However, formalin inactivated
vaccines have been developed for human use, but the dis-
tribution is limited to high-risk occupation staff [5,6].
Currently there are a few vaccines available for use in live-
stock: vaccines based on the live-attenuated Smithburn
strain [7] and formalin inactivated virus preparations [8].
The Smithburn virus vaccine is suggested to induce life-
long protection, but has retained the ability to induce
abortions and teratogenic effects in livestock [9,10]. The
inactivated virus vaccines are safe, but less immunogenic
and require annual booster vaccinations [11]. Previously,
two vaccine candidates have been proposed and tested for
their safety and efficacy in animal trials: a naturally atten-
uated RVFV isolate from a benign human case in the Cen-
tral African Republic, Clone 13 [12] and a human virus
isolate of RVFV attenuated in cell culture by 5-fluorouracil
treatment, MP12 [13,14]. Although Clone 13 and MP12
were shown to be safe and immunogenic in mice and in
cattle and sheep, respectively [12], the MP12 vaccine was
found teratogenic for pregnant sheep if used during the
first trimester [15].
In addition to the adverse effects previously shown for
attenuated RVF vaccines, there are considerable safety
concerns regarding viral vaccines based on highly patho-
genic organisms due to the risk for exposure or escape of
live agents during the manufacturing process. In addition,
there is also a risk of insufficient inactivation or emer-
gence of revertants, when large quantities of virulent virus
strains are handled. Because of these shortcomings, new
RVF vaccine strategies ought to be considered. Genetic
immunisation is an attractive alternative, since the anti-
gens are produced by the host cells and the presentation
resembles natural infections by intracellular parasites. It is
also cost-effective and circumvents the need for elevated
biosafety level facilities [16]. Genetic vaccines are also less
vulnerable to elevated temperatures during storage and
transportation, which are important factors when per-
forming vaccinations in developing countries [17]. These
characteristics make DNA vaccines uniquely suited for
vaccine production against highly pathogenic organisms,
such as RVFV [18,19].
The RVFV is a three segmented negative stranded RNA
virus. The (L)arge segment encodes a RNA dependent
RNA polymerase and the (M)edium segment encodes two
glycoproteins (GN and GC), a 78 kDa protein as well as a
non-structural protein (NSm). The (S)mall segment
encodes a non-structural protein (NSs) and the immuno-
genic and highly expressed nucleocapsid protein (N) [3].
Despite an abundance of the N protein in the virus and in
the infected cell, this protein is not generally associated
with protective immunity. However, a recent study has
shown that a proportion of mice inoculated with purified
RVFV N proteins were protected against virus challenge
[20]. Although antibodies targeting the RVFV glycopro-
teins are recognized for their protective properties [21]
contradictory results regarding the level of protection after
DNA vaccination have been presented [20,22,23].
In this study we evaluate the induced immune responses
and the conferred protection in mice after genetic immu-
nisation with cDNA encoding the structural proteins of
RVFV. The elicited immune responses towards the N, GN,
GC and GN/GC proteins after gene-gun immunisation were
analysed and the protective abilities of the N and the GN/
GC construct were tested by virus challenge.
Methods
Cells and viruses
BHK-21 (ATCC number CCL-10) cells were maintained in
Glasgow MEM (GIBCO, Invitrogen, Carlsbad, CA) sup-
plemented with 5% FCS, 1.3 g/l Tryptose (Difco™, Becton,
Dickinson and Company, Sparks, MD), 10 mM HEPES, 1
mM sodium pyruvate, 100 U penicillin/ml and 100 μg/ml
streptomycin at 37°C/5% CO2. The working stocks of
RVFV and cDNA constructs, originated from the ZH548
wild-type strain, isolated from a human case in Egypt in
1977 [24]. Viral stocks were prepared and titrated on
monolayers of BHK-21 cells and the cDNA sequences are
found under the GenBank accession numbers AF134534
and DQ380206[25,26].
Production of DNA vaccine
For genetic immunisation and eukaryotic expression,
cDNAs encoding N, GN/GC, GN and GC were inserted into
pcDNA3.1/V5-His®  TOPO (Invitrogen). The primer
sequences used for cDNA amplification and subsequent
cloning are shown in Table 1. The correctness of each
cDNA construct was confirmed by sequencing (MWG-
Biotech) and the corresponding gene products were veri-
fied through transfection of mammalian cells followed by
immunofluorescence analysis. A cDNA construct
(pcDNA3.1) encoding the N protein (PUU-N) of the Puu-
mala hantavirus (Puumala virus Umeå/hu [GenBank:
AY526219] [27,28] was used as a control. The preparation
of gene-gun cartridges has previously been described [28].
Briefly, 50 μg aliquots of the above plasmid DNA prepara-
tions were precipitated on 25 mg of 1 μm gold beads andVirology Journal 2009, 6:6 http://www.virologyj.com/content/6/1/6
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subsequently used to coat the inner wall of Tefzel tubings
according to the manufacturer's instructions (BioRad Lab-
oratories, Hercules, CA). Each gene-gun cartridge deliv-
ered approximately 1 μg of DNA.
Animal immunisation and infection
Female BALB/c mice, six to eight weeks old, were used in
this study. Before immunisation the mice were thor-
oughly shaved on the abdomen and vaccinated with
cDNA encoding the antigens using a gene-gun (Helios™,
BioRad Laboratories). The cDNA was administrated four
times with two to three week intervals. The primary
immunisation was performed using four gene-gun car-
tridges and the following three boosters with two car-
tridges. Blood samples were collected three, five, seven
and nine weeks after the primary immunisation. In order
to study the immune responses post infection (p.i.) and
the effectiveness of the genetic vaccines, mice were
injected intraperitoneally (i.p.) with RVFV diluted in ster-
ile PBS to a final volume of 100 μl. Infected animals were
kept in micro-isolator cages inside an animal isolator (Bell
Isolation Systems Ltd, Livingston, Scotland) and all
manipulations involving infected animals or viable virus
were performed within a BSL-3 laboratory. During the
experimental procedures the animals were monitored
daily and were kept with free access to food and water.
Mice found in a moribund condition (fatigue and
"hunchback-like posture") were instantly euthanized.
This project was approved by The Animal Research Ethics
Committee of Umeå University, Sweden.
Evaluation of immune response
To evaluate and compare the immune responses after vac-
cination and infection, eight animals were vaccinated
with cDNA encoding N, four with cDNA containing the
open reading frame of the GN/GC poly-protein and two
groups, each containing four animals, were immunised
with either the GN or the GC construct. To analyse the
immune responses after infection, one group consisting of
nine mice were infected with 2.4 × 104 PFU of RVFV. At
day 14 p.i. the animals were euthanized and samples col-
lected. As negative controls, four mice were immunised
with the pcDNA3.1 vector without insert and another four
mice were injected with sterile PBS and kept under the
same conditions.
Challenge study
A total of 30 mice were used in the challenge study, eight
of which were vaccinated with cDNA encoding the RVFV
N protein and eight with the GN/GC construct. As controls,
eight animals were vaccinated with an irrelevant gene
(encoding the N protein of the Puumala virus, PUU-N)
and six animals with pcDNA 3.1 vectors without insert.
After four rounds of immunisations, half of the mice of
each vaccination group were challenged with 2.4 × 103
and half with 2.4 × 104 PFU of RVFV. Blood samples were
collected every alternate day until the end of the experi-
ment at day 17 p.i.
Antigen production and purification
For antigen production and prokaryotic expression, cDNA
encoding the full-length N protein (aa 1–245) of RVFV
was ligated into pET-14b (Novagen, Darmstadt, Ger-
many) and cDNA encoding truncated N derivatives, N1
(aa 1–100), N2 (aa 71–170), N3 (aa 141–245), N1/2 (aa
1–170) and N2/3 (aa 71–245), were inserted into
pET101/D-TOPO® or pET151/D TOPO® (Invitrogen). The
primer sequences are shown in Table 1.
DNA constructs expressing the N protein and truncated N
derivatives were expressed in Escherichia coli (E. coli) BL21
DE3 (Invitrogen). Briefly, transformed bacteria were
grown in Luria-Bertani media supplemented with 100 μg/
ml carbencillin to OD A600 of 0.7. Expression of the anti-
gens was induced by the addition of isopropyl-beta-D-thi-
ogalactopyranoside (IPTG) at a final concentration of 0.5
Table 1: Primers sequences
Construct Forward primer sequences Reverse primer sequences
aGN/GC 5'-ATGGAAGACCCCCATCTCAGAAA-3' 5'-CTATGAGGCCTTCTTAGTGGC-3'
aGN 5'-ATGGAAGACCCCCATCTCAGAAA-3' 5'-TGCTGATGCATATGAGACAATC-3'
aGC 5'-ATGTGTTCAGAACTGATTCAGGCA-3' 5'-CTATGAGGCCTTCTTAGTGGC-3'
aN 5'-CACCATGGACAACTATCAAGAGCTT-3' 5'-GGCTGCTGTCTTGTAAGCC-3'
aPUU-N 5'-CACCATGAGTGACTTGACAGATATCCA-3' 5'-TATCTTAAGTGGATCCTGATTAGATA-3'
bN 5'-CACCATGGACAACTATCAAGAGCTT-3' 5'-GGCTGCTGTCTTGTAAGCC-3'
bN1 5'-CACCATGGACAACTATCAAGAGCTT-3' 5'-ATCCCGGGAAGGATTCCCT-3'
bN2 5'-CACCATGATGATGAAAATGTCGAAAG-3'        5'-TTAAGAGTGAGCATCTAATATT-3'
bN3 5'-CACCATGCCGAGGCATATGATGCACC-3' 5'-GGCTGCTGTCTTGTAAGCC-3'
bN1/2 5'-CACCATGGACAACTATCAAGAGCTT-3' 5'-AGAGTGAGCATCTAATATT-3'
bN2/3 5'-CACCATGATGATGAAAATGTCGAAAG-3' 5'-TAAGGCTGCTGTCTTGTAAGCC-3'
a Eukaryotic expression.
b Prokaryotic expression.Virology Journal 2009, 6:6 http://www.virologyj.com/content/6/1/6
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mM. The purification of the full length N protein
expressed from a poly-histidine-fusion vector was per-
formed with metal chelating chromatography using Ni-
NTA Agarose (Qiagen GmbH, Hilden, Germany), essen-
tially as described previously [29]. N protein preparations
used for the lymphocyte proliferation assay were purified
further with Triton X-114 (Sigma-Aldrich Inc., St. Louis,
MO) to remove contaminating amounts of endotoxins
[30]. Each batch was tested for unspecific stimulation of
splenocytes before use.
Enzyme-linked immunosorbent assay (ELISA), Western 
blot and Immunofluorescence analysis (IFA)
Indirect ELISA (total Ig) was performed using microtiter
plates (NUNC-immuno™ MaxiSorp, Nalgene Nunc Inter-
national, Rochester, NY) coated with 3 μg/ml of purified
recombinant N protein as previously described [31].
Wells lacking the primary antibody were used to establish
the background levels and negative or pre-immune sera
were used to determine unspecific binding.
Western blot was performed using E. coli extracts contain-
ing the complete N protein or truncated variants thereof
(N1, N2, N3, N1/2, N2/3). The separated proteins were
transferred to Immobilon TMP transfer membranes (type
PVDF, Millipore Co., USA). Membranes containing the
antigens were incubated with serum samples from indi-
vidual mice at dilution 1:600 in parallel with internal con-
trols, either an anti-V5 antibody (Invitrogen) diluted
1:5000 or a mouse anti-poly-histidine antibody (ZYMED®
Laboratories, S. San Francisco, CA) diluted 1:3000. A
horseradish peroxidase (HRP) conjugated rabbit anti-
mouse Ig antibody (DacoCytomation, Glostrup, Den-
mark) diluted 1:2000 was used as secondary antibody.
The antibody-antigen complexes were visualised with
enhanced chemiluminescence (ECL, Amersham Bio-
science, Uppsala, Sweden). The blotting and incubation
procedures have previously been described in detail [28].
For IFA, BHK-21 cells were grown on cover slips and
infected with ZH548 at MOI 1, or transfected with cDNA
constructs using FuGene™ reagent according to the manu-
facturer's instructions (Roche Diagnostics, Basel, Switzer-
land). At 36 h p.i. or 48 h post transfection the cells were
fixed with 3% paraformaldehyde in PBS (for anti-glyco-
protein antibody detection) or methanol (for anti-N anti-
body detection). Labelling was performed with mouse
sera diluted 1:200, followed by visualisation with an
Alexa Fluor™ 488 (Molecular probes, Invitrogen) second-
ary antibody at dilution 1:5000. The expression of the
antigens was verified using an anti-V5 antibody (Invitro-
gen) diluted 1:5000, positive sera from previously
infected mice or monoclonal antibodies directed against
the GN and GC proteins, kindly provided by Dr. George
Ludwig (USAMRIID, Fort Detrick, MD) at predetermined
dilutions.
Lymphocyte proliferation test
The lymphocyte proliferation assay was performed as
described earlier [32]. Briefly, spleen cells of five mice vac-
cinated with cDNA encoding the full length N protein of
RVFV were prepared in RPMI 1640 (GIBCO, Invitrogen)
supplemented with 5% FCS, 2 mM sodium pyruvat, 2.5 ×
10-5 M β-Mercaptoethanol and 50 μg/ml gentamicin sul-
phate. After washing the spleen cells three times in cell
culture media by centrifugation at 600 × g, the lym-
phocytes were resuspended to 4 × 105 cells/ml. Aliquots
(100 μl) of the cells were seeded to 96-wells flat-bottom
microplates (Nalgene Nunc International) in cell culture
media containing the antigen at different concentrations.
After two days incubation at 37°C/5% CO2, 1 μCi of
3HTdR (5'-3H Thymidine spec.act 14.4 Ci/mmol, Amer-
sham Biosciences) was added. After an additional 16–18
hr of metabolic labelling, the cells were harvested on GF/
C filters (Inotech AG, Basle, Switzerland) and analysed for
incorporated radioactivity using a liquid scintillation
counter (TriCarb 2500 TR, Packard Instruments, Meriden,
CT). Spleen cells obtained from four mice immunised
with the plasmid vector without insert constituted the
negative control. The stimulation index (SI) was calcu-
lated as the ratio of radioactivity incorporated into cells
from vaccinated mice and the count rate in cells from con-
trol mice.
Plaque reduction neutralisation test (PRNT)
Heat-inactivated mouse sera including positive and nega-
tive controls, were serially diluted three-fold in PBS and
incubated with a virus suspension containing about 30
plaque forming units (PFU) of RVFV. The mixtures were
incubated for 90 min at 37°C and thereafter used to infect
monolayers of BHK-21 cells in 6-well tissue culture plates
(NUNC tissue culture, Nalgene Nunc International). After
an adsorption period of 30 min at 37°C, the cells were
rinsed with PBS and incubated with cell culture media
containing 1% Carboxy-Methyl Cellulose (Aquacide II,
Calbiochem®, Merck, CA) for six days at 37°C/5%CO2.
The cells were subsequently fixed with 10% formalde-
hyde, washed with water and counter-stained with 1%
crystal violet in water containing 20% ethanol and 0.7%
NaCl. The PRNT50 titer was calculated as the reciprocal of
the highest serum dilution that reduced the number of
plaques by 50%, as compared to the virus control.
Statistical methods
The outcome of the challenge was evaluated using the
Fisher exact test (Epi Info™, Version 3.5). Quantitative var-
iables were based on measurements of at least two inde-
pendent experiments containing duplicate samples.Virology Journal 2009, 6:6 http://www.virologyj.com/content/6/1/6
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Variables are expressed as means and the error bars repre-
sent the standard deviation.
Results
Antibody response after immunisation with cDNA 
encoding the N protein
Genetic vaccination with cDNA encoding the N protein
resulted in a strong humoral immune response in all
mice. Anti-N specific antibodies (total Ig) were detected
by ELISA already after the first immunisation and were
followed by a large increase in titers after additional vacci-
nation rounds (Fig 1). However, despite the strong anti-
body response observed after genetic vaccination with
cDNA encoding the N protein, RVFV neutralising antibod-
ies were not detected by PRNT (data not shown).
Since previous studies have shown that strong antigenic
determinants are located near the amino-terminus of the
N protein of other viruses in the Bunyaviridae  family
[33,34], antigenic regions of the RVFV N protein were
investigated in more detail. Serum samples from seven
mice immunised with cDNA encoding the complete N
protein and nine from infected mice were analysed and
compared by Western blot for reactivity towards the N
protein and truncated N proteins (Fig 2). A strong and
uniform reactivity profile towards the full-length protein
was found in all animals and most sera displayed a similar
Anti-N specific antibody responses (total Ig) after gene-gun vaccination with cDNA encoding the RVFV N protein Figure 1
Anti-N specific antibody responses (total Ig) after gene-gun vaccination with cDNA encoding the RVFV N pro-
tein. The curves correspond to the mean titers in individual mouse sera measured by ELISA. The error bars represent the 
standard deviation between replicates. Arrows along the X-axis illustrate the time points of vaccination.Virology Journal 2009, 6:6 http://www.virologyj.com/content/6/1/6
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but weaker reactivity towards the truncated N1/2 and N2/
3 proteins. Surprisingly, the amino-terminus (N1 protein)
was only recognised by sera from immunised mice and
not by any serum obtained from infected mice. Further-
more, the central part (N2) and the carboxy-terminus
(N3) were neither recognised by sera from infected nor
immunised mice (Fig 2).
Proliferative response subsequent immunisation with 
cDNA encoding the N protein
Spleen cells from vaccinated mice were assayed to address
the question if genetic immunisation induces antigen
dependent cell proliferation. The obtained results indicate
that lymphocytes from five animals immunised with the
N construct displayed antigen induced proliferation when
up to 1 μg/ml of the purified and Triton X-114 extracted
N protein was added (Fig 3). However, higher concentra-
tions of the antigen (5–10 μg/ml) resulted in cell toxicity
and cell death. The stimulation index (SI) was determined
at between 4 and 6 when spleen cells were stimulated with
1 μg/ml of the purified N antigen (Fig 3). Background lev-
els, independent of the antigen concentration, were
observed in lymphocytes from control mice. Incorporated
radioactivity in spleen cells stimulated by 0.5–1 μg of
ConA was approximately 10–20 times higher that of the
negative controls and 4–5 times higher than any cell sam-
ple collected from immunised mice.
Humoral response after immunisation with cDNA 
encoding the glycoproteins
All mice sero-converted after immunisation with cDNA
encoding the GN/GC proteins or the GN protein but only
two out of four after vaccination with cDNA encoding the
GC protein, as detected by IFA performed on infected cells.
The virus neutralising antibody titers after GC and GN vac-
cination were in the lower range, less than 25 and between
25 to 75, respectively. However, the GN/GC vaccinated
mice acquired considerably higher titers, up to 225 (data
not shown). These results indicate that vaccination with
the GN/GC construct resulted in higher virus neutralising
antibody titers than the use of cDNA encoding for the
individual glycoproteins.
Challenge of gene-gun vaccinated mice
To evaluate the degree of protection against RVFV infec-
tion after gene-gun vaccination, a new batch of mice was
divided into groups of eight and immunised with either
cDNA encoding the N or the GN/GC proteins. Two control
groups, eight mice immunised with the PUU-N construct
and six mice immunised with vectors without insert were
also included. The groups were further divided into two
subgroups and challenged with 2.4 × 103 or 2.4 × 104 PFU
of RVFV (Table 2). As the lethality of the ZH548 strain was
found low for the 15 to 17 weeks old BALB/c mice, the
protection conferred by vaccination was also based on
development of clinical signs and increase in N specific
antibody titers (the latter was only applied for GN/GC vac-
cinated mice) upon challenge. In the GN/GC vaccination
group, all mice responded to the vaccination and sero-
converted, while only five out of eight mice developed
virus neutralising titers ranging from 25 to 75 (Table 2).
Mice vaccinated with the N construct induced a strong
antibody response, with ELISA titers ranging from 2.5 ×
104 to 4.5 × 104, after four immunisations (data not
shown).
Since differences in clinical signs could not be ascribed to
the different challenge doses, the two subgroups within
Western blot reactivity towards the N protein and truncated variants thereof Figure 2
Western blot reactivity towards the N protein and truncated variants thereof. (A) Schematic presentation of the 
full length and deleted variants of the RVFV N antigens. Different filter strips represent different recombinant proteins. The 
sera were obtained from (B) seven mice vaccinated with cDNA encoding the complete N protein or (C) nine mice infected 
with RVFV. The sera were collected after four immunisations or 14 days p.i., respectively. Antibodies binding to the amino- or 
carboxy-terminal His-tag or V5-tag of the recombinant proteins were used as positive controls (Ctrl).Virology Journal 2009, 6:6 http://www.virologyj.com/content/6/1/6
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each vaccine group were consolidated and evaluated
together. In the groups of mice immunised with the N or
the GN/GC constructs, four of eight and five of eight ani-
mals, respectively, displayed no clinical signs during the
entire experiment (Table 2). Despite the large proportion
of animals without RVF clinical signs in the GN/GC vacci-
nation group, extensive viral replication after infection
was indicated by high N specific antibody titers, similar to
the titers observed for the control animals (data not
shown). Apart from one casualty, due to a moribund con-
dition, in the N vaccinated group, no major differences in
the severity of the clinical manifestations were observed
between the GN/GC and N vaccinated mice after challenge.
In contrast, all animals in the two control groups dis-
Lymphocyte proliferation test performed on spleen cells from mice vaccinated with cDNA encoding the N protein Figure 3
Lymphocyte proliferation test performed on spleen cells from mice vaccinated with cDNA encoding the N 
protein. The curves correspond to the incorporated radioactivity measured for cells of five immunised mice and the dotted 
curves represent four control mice immunised with the vector without insert. The error bars represent the standard deviation 
between replicates. The spleen cells were stimulated for proliferation using the indicated N antigen concentrations (0.1, 0.3, 
1.0 and 3.0 μg/ml).Virology Journal 2009, 6:6 http://www.virologyj.com/content/6/1/6
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played either clinical signs of infection followed by com-
plete recovery (12/14) or were sacrificed due to a
moribund condition (2/14) (Table 2). Significant protec-
tion against RVF clinical signs was observed among the N
vaccinated mice (p = 0.0096, Fisher exact test) and the GN/
GC vaccinated mice (p = 0.0021, Fisher exact test) as com-
pared to the controls.
Discussion
RVF is an important emerging zoonotic infection and
early efforts to protect animals and humans resulted in
development of attenuated and inactivated virus vaccines.
Vaccines based on live attenuated RVFV strains have
shown to induce long-lasting protection in contrast to
inactivated virus vaccines, which require multiple booster
doses to retain a protective immunity [11]. Unfortunately,
teratogenic effects and the ability to cause abortions limit
the likelihood for wide use and distribution of the current
vaccines based on attenuated RVFV strains. As the existing
vaccines have such shortcomings, efforts to design safer
and more efficient RVF vaccines need to be undertaken.
We have investigated the prospect of employing genetic
immunisation against RVF. The DNA vaccine platform
has been extensively studied during the last decade. How-
ever, the breakthrough has been on halt until recently
when the first licensed products became available, such as
the vaccine against West Nile virus infection in horses and
a vaccine for use in salmon against the hematopoietic
necrosis virus [35]. The DNA vaccine technology is espe-
cially suitable against pathogens such as RVFV, since the
need of elevated biosafety facilities are circumvented and
the stability of these vaccines allow distribution in devel-
oping countries lacking the logistics to maintain a "cold-
chain".
In this study, the immune responses in mice after genetic
immunisation with RVFV cDNA encoding the N protein,
the glycopolyprotein GN/GC, and the separate GC and GN
proteins were analysed. The N and the GN/GC constructs
displayed the most promising results regarding the elic-
ited immune response and were evaluated further for the
ability to confer protection in a subsequent challenge
study.
After gene-gun vaccination with the N construct, high
antibody titers were repeatedly induced along with an
antigen induced proliferative cellular response. Interest-
ingly, no clinical signs were observed after challenge in
50% of the animals (compared to 100% in the control
group) despite the lack of detectable levels of neutralising
antibodies after vaccination. The observed protection
might be explained by cell-mediated immune factors as
indicated by the dose-dependent proliferation of spleen
cells from the immunised animals. Nevertheless, the char-
acteristics of the proliferating cells remain to be investi-
gated further. Analogous results were previously found
after vaccination with the purified RVFV N protein when
protection was obtained in 60% of the vaccinated mice
[20]. Also, a recent study using the Toscana virus (Phlebo-
virus, Bunyaviridae) reported approximately 60% survival
upon challenge after immunisation with the recombinant
Table 2: Neutralising antibody titers and outcome after challenge after DNA vaccination against RVFV
Vaccine group No. of animals PRNT50 titersa Challenge dose Outcome after challenge with RVFV
Asymptomatic Clinical signsb Deathsc
N 4 < 25 2.4 × 103 13
4 < 25 2.4 × 104 31
GN/GC 4 25 – 75 2.4 × 103 22
4 25 – 75 2.4 × 104 31
Ctrl/PUU-N 4 - 2.4 × 103 31
4 - 2.4 × 104 31
Ctrl/pcDNA3.1 3 - 2.4 × 103 3
3 - 2.4 × 104 3
a Virus neutralising antibody titers after vaccination.
b Number of animals displaying clinical signs (ruffled fur/shivering), followed by complete recovery.
c Number of animals displaying a moribund condition (fatigue/"hunchback-like posture") followed by euthanization.Virology Journal 2009, 6:6 http://www.virologyj.com/content/6/1/6
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N protein, probably due to a cellular mediated immune
response [36].
Previous studies of N proteins of Hantaviruses revealed
that strong B-cells epitopes are located near the amino-ter-
minus [33,34]. However, this does not seem to be the case
for RVFV N. Genetic immunisations are in general
believed to mimic the natural presentation of antigens
[37], but interestingly, while the sera of immunised mice
recognized the amino-terminal part (aa 1–100) of the N-
protein, sera of the infected animals did not. The lack of
reactivity towards the central (N2) and the C-terminal
(N3) parts could either be explained by a distorted confor-
mation of the encoded antigens or disruption of epitope-
regions within the N protein.
In this study, antibodies towards the glycoproteins were
induced after genetic vaccination, but virus neutralisation
was only observed in sera of mice immunised with cDNA
containing the GN gene. This observation is in accordance
with earlier findings, where GN has been shown to possess
antigenic determinants important for protection, while
GC does not [38,39]. However Besselar and co-workers
found neutralising epitopes associated with protection in
the GC, as well as in the GN protein [40]. The absence of
neutralising antibodies after gene-gun vaccination using
the GC construct alone might be explained by incorrect
folding of the expressed antigen, since neutralising anti-
bodies elicited by the glycoproteins are often found to be
conformation dependent [41].
The RVFV glycoproteins have been used in several protec-
tion studies, utilizing different vaccination strategies and
animal models. The protective effect varied from no/low
to complete protection depending on the administration
strategy, antigen and animal model used [20-22,38-
40,42]. In this study, the majority of the GN/GC vaccinated
mice were protected against RVF. However, the incom-
plete protection found was unexpected as a similar study,
using analogous GN/GC constructs (RVFV-NSm), reported
complete protection of mice after challenge [22]. On the
other hand, intramuscular inoculation of cDNA encoding
the GN/GC polyprotein did not induce neutralising anti-
bodies and did not protect against RVFV challenge [20].
Interestingly, a recent study reported that dual expression
of the N and the GN/GC proteins may generate RVF Virus-
Like Particles (VLPs) [43], and the formation of VLPs after
genetic immunisation is hypothesised to be the reason for
the high virus neutralising antibody titers induced by the
genetic West Nile virus vaccine [44]. Perhaps, by using a
similar approach, and introducing cDNA encoding the N
and the GN/GC  proteins of RVFV, a fully protective
immune response might be induced.
In summary, while DNA vaccination against RVF induced
strong humoral and proliferative immune responses in
vaccinated mice, complete protection after challenge was
not achieved. Nevertheless, naked DNA vaccines may con-
stitute a promising strategy for vaccine development and
this study provides insight for the basis of a future devel-
opment of an efficacious DNA vaccine against RVF.
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